The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Differences in the Conformational Energy Landscape of CDK1 and CDK2 Suggest a Mechanism for Achieving Selective CDK Inhibition
Open accessAbstract
Dysregulation of the cell cycle characterizes many cancer subtypes, providing a rationale for developing cyclin-dependent kinase (CDK) inhibitors. Potent CDK2 inhibitors might target certain cancers in which CCNE1 is amplified. However, current CDK2 inhibitors also inhibit CDK1, generating a toxicity liability. We have used biophysical measurements and X-ray crystallography to investigate the ATP-competitive inhibitor binding properties of cyclin-free and cyclin-bound CDK1 and CDK2. We show that these kinases can readily be distinguished by such inhibitors when cyclin-free, but not when cyclin-bound. The basis for this discrimination is unclear from either inspection or molecular dynamics simulation of ligand-bound CDKs, but is reflected in the contacts made between the kinase N- and C-lobes. We conclude that there is a subtle but profound difference between the conformational energy landscapes of cyclin-free CDK1 and CDK2. The unusual properties of CDK1 might be exploited to differentiate CDK1 from other CDKs in future cancer therapeutic design.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Several Cdk2 inhibitors bind more tightly in the presence of the cyclin subunit25.”
From Allostery governs Cdk2 activation and differential recognition of CDK inhibitors (2021) · cites this paper as [25]
In the citing paper
“In the crystal structure of flavopiridol bound to the Cdk2:cyclinA dimer25, the inhibitor forms hydrogen bonds with the K33 residue, the catalytic glutamate E51 and a water molecule (Extended Data Fig. 1, bottom).”
From Allostery governs Cdk2 activation and differential recognition of CDK inhibitors (2021) · cites this paper as [25]
In the citing paper
“Second, the model recapitulates the positive binding cooperativity between cyclin and the Cdk2 inhibitors25 and reveals that it can be partitioned into two allosteric effects, quantified by the allosteric coupling parameters β and γ (Fig. 4d).”
From Allostery governs Cdk2 activation and differential recognition of CDK inhibitors (2021) · cites this paper as [25]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Phaser crystallographic software
McCoy, A. J., Grosse-Kunstleve, R. W., Adams, P. D., Winn, M. D., Storoni, L. C., & Read, R. J. (2007) · Journal of Applied Crystallography · doi:10.1107/s0021889807021206 · Cited by 20,612
Kabsch, W. (2010) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444909047337 · Cited by 16,463
Overview of the CCP 4 suite and current developments
Winn, M. D., Ballard, C. C., Cowtan, K. D., Dodson, E. J., Emsley, P., Evans, P. R., Keegan, R. M., Krissinel, E. B., Leslie, A. G. W., McCoy, A., et al. (2011) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444910045749 · Cited by 12,353 · cited 1×
“The programs within the CCP4i2 software package (Potterton et al., 2018; Winn et al., 2011) were employed throughout the structure determination process.”
MethodThe history and future of targeting cyclin-dependent kinases in cancer therapy
Asghar, U., Witkiewicz, A. K., Turner, N. C., & Knudsen, E. S. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4504 · Cited by 1,767
Discovery of a potent and selective inhibitor of cyclin-dependent kinase 4/6
Toogood, P. L., Harvey, P. J., Repine, J. T., Sheehan, D. J., VanderWel, S. N., Zhou, H., Keller, P. R., McNamara, D. J., Sherry, D., Zhu, T., et al. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm049354h · Cited by 513 · cited 1×
“Dysregulation of CDK activity is frequently associated with inappropriate cell-cycle progression and, as a result, various members of the family have been pursued as targets for anti-cancer drug design (Kim et al., 2013; Toogood et al., 2005; Whittaker et al., 2017).”
BackgroundInhibitors of cyclin-dependent kinases as cancer therapeutics.
Whittaker, S. R., Mallinger, A., Workman, P., & Clarke, P. A. (2017) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.02.008 · Cited by 384
Kim, S., Loo, A., Chopra, R., Caponigro, G., Huang, A., Vora, S., Parasuraman, S., Howard, S., Keen, N., Sellers, W., et al. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.targ-13-pr02 · Cited by 106
Cited by
Cell cycle on the crossroad of tumorigenesis and cancer therapy
Liu, J., Peng, Y., & Wei, W. (2022) · Trends in Cell Biology · doi:10.1016/j.tcb.2021.07.001 · Cited by 372
Allostery governs Cdk2 activation and differential recognition of CDK inhibitors
Majumdar, A., Burban, D. J., Muretta, J. M., Thompson, A. R., Engel, T. A., Rasmussen, D. M., Subrahmanian, M. V., Veglia, G., Thomas, D. D., & Levinson, N. M. (2021) · Nature Chemical Biology · doi:10.1038/s41589-020-00725-y · Cited by 65
Metadata
- Authors
- Wood, D. J., Korolchuk, S., Tatum, N. J., Wang, L.-Z., Endicott, J. A., Noble, M. E. M., & Martin, M. P.
- Venue
- Cell Chemical Biology
- Publisher
- Elsevier BV
- Published
- 2019-01
- Volume
- 26
- Issue
- 1
- Pages
- 121-130.e5
- ISSN
- 2451-9448 (ISSN-L)
- 2451-9456
- OpenAlex
- W2901086483
- Cited by
- 168
- References
- 7
- FWCI
- 2.19
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Differences in the Conformational Energy Landscape of CDK1 and CDK2 Suggest a Mechanism for Achieving Selective CDK Inhibition. https://app.cochat.ai/papers/10.1016/j.chembiol.2018.10.015
- The paper
- Wood, D. J., Korolchuk, S., Tatum, N. J., Wang, L.-Z., Endicott, J. A., Noble, M. E. M., & Martin, M. P. (2019). Differences in the Conformational Energy Landscape of CDK1 and CDK2 Suggest a Mechanism for Achieving Selective CDK Inhibition. Cell Chemical Biology. https://doi.org/10.1016/j.chembiol.2018.10.015
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.